Research Projects & Grants

Federal

  • To elicit patient and caregiver perceptions of the disease course of PDAC, values and preferences regarding treatment and the role of palliative care, Role: Investigator, Department of Defense, (05/2024) Status: Approved
  • To test the feasibility of a digitally enhanced CHW-led intervention focusing on patient and caregiver education, clarifying patient and caregiver goals, advanced care planning, and early palliative care engagement in a pilot study of Hispanic patients with PDAC, Role: Investigator, Department of Defense, (12/2024) Status: Approved

For Profit Organization

  • SWOG-S0820: A double blind placebo-controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers in patients with stage 0-III colon cancer, phase III - preventing adenomas of the colon with eflornithine and sulindac (PACES), Role: Investigator, Southwest Oncology Group, (09/2024 - 09/2025) Status: Approved
  • SWOG-A081105: randomized study of Erlotinib VS Observation in patients with completely resected Epidermal Growth Factor Receptor (EGFR) mutant Non-small Cell Lung Cancer (NSCLC), Role: Investigator, Southwest Oncology Group, (09/2024 - 09/2025) Status: Approved
  • Amgen Inc., 20190135: A Phase 1b Study Evaluating the Safety, Tolerability, and Efficacy of AMG 510 (plNN Sotorasib) in Combination with Panitumumab and in Combination with Panitumumab and Chemotherapy in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H), Role: Investigator, Amgen, Inc., (06/2024 - 06/2025) Status: Approved
  • J2J-MC-JZLH EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence, Role: Investigator, Eli Lilly & Co., (06/2024 - 06/2025) Status: Approved
  • Amgen 20190135: A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (plNN Sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation, Role: Investigator, Amgen, Inc., (02/2025 - 02/2026) Status: Approved
  • SWOG S1418/BR006: A randomized phase III trial to evaluate the efficacy and safety of MK-3457 (Pembrolizumab) as adjuvant therapy for triple receptor-negative breast cancer with = 1 cm residual invasive cancer or positive lymph nodes (ypN+) after neoadjuvant chemotherapy, Role: Investigator, Southwest Oncology Group, (12/2024 - 12/2025) Status: Approved
  • Amgen 20190135: A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation Amgen 20190135-C: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol C), Role: Investigator, Amgen, Inc., (12/2024 - 12/2025) Status: Approved
  • ATARA Biotherapeutics, Inc. ATA129-EBV-302: Multicenter, Open Label, Phase 3 study of Tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-associated post-transplant lymphoproliferative disease after failure of Rituximab or Rituximab and Chemotherapy (ALLELE study), Role: Investigator, Atara Biotherapeutics, Inc., (12/2024 - 12/2025) Status: Approved
  • Southwest Oncology Group (SWOG) S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in rare tumors, Role: Investigator, Southwest Oncology Group, (12/2024 - 12/2025) Status: Approved
  • A Phase 3 Open-label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03), Role: Investigator, AstraZeneca Pharmaceuticals, L.P. (USA), (01/2024 - 01/2026) Status: Approved
  • SWOG EA5142:adjuvant nivolumab in resected lung cancers (ANVIL) a randomized phase III study of nivolumab after surgical resection and adjuvant chemotherapy in non-small cell lung cancers, Role: Investigator, Southwest Oncology Group, (11/2024 - 11/2025) Status: Approved
  • SWOG-S1216: a phase III randomized trial comparing androgen deprivation therapy + TAK-700 with androgen deprivation therapy + bicalutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer, Role: Investigator, Southwest Oncology Group, (10/2024 - 10/2025) Status: Approved
  • SWOG A151216: adjuvant lung cancer enrichment marker identification and sequencing trial (ALCHEMIST), Role: Investigator, Southwest Oncology Group, (10/2024 - 10/2025) Status: Approved
  • Apollomics Inc. APL-101-01 (SPARTA): Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors, Role: Investigator, Apollomics Inc., (09/2024 - 09/2025) Status: Approved
  • Novartis CLDK378A2X01B: An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib, Role: Investigator, Novartis Pharmaceuticals Corporation, (01/2023 - 01/2024) Status: Completed
  • Astellas 8951-CL-0301: A phase 3, global, multi-center, double-blind, randomized, efficacy study of Zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 as first-line treatment of subjects with Claudin (CLDN) 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, Role: Investigator, Astellas Pharma US, Inc., (06/2022 - 06/2023) Status: Completed
  • C3441021: A Phase 3, Randomized, Double-Blind, Placebo-Controlled study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (TALAPRO-2), Role: Investigator, Pfizer Inc., U.S. Pharmaceuticals Group, (07/2021 - 07/2022) Status: Completed
  • Novartis CACZ885V2301: A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subjects with non-small cell lung cancer (NSCLC) previously treated with PD(L)1 inhibitors and platinum-based chemotherapy (CANOPY-2), Role: Investigator, Novartis Pharmaceuticals Corporation, (09/2020 - 09/2021) Status: Completed
  • SWOG -EAY131: Molecular analysis for therapy choice (MATCH), Role: Investigator, Southwest Oncology Group, (08/2019 - 08/2020) Status: Completed
  • SWOG A041701: A randomized phase II/III study of conventional chemotherapy +/- uproleselan (GMI-1271) in older adults with acute Myeloid Leukemia receiving intensive induction chemotherapy, Role: Investigator, Southwest Oncology Group, Status: Completed
  • LUNGMAP, “A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Preciously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)” S1900F, “A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)”, Role: Investigator, Southwest Oncology Group, Status: Completed
  • A Phase 1b/2 Study Assessing the Safety and Efficacy of Evexomostat (SDX-7320) in Combination with a PI3K Pathway Inhibitor plus Fulvestrant in Postmenopausal Women with Advanced Breast Cancer and PII3K Pathway Alterations Who Have Progressed on or Following Endocrine Therapy plus a CDK4/6 Inhibitor, Role: Investigator, SynDevRx, Inc., (02/2025 - 02/2026) Status: Approved

Internal

  • Investigator initiated CIPNGRASP: A pilot study of intraneural facilitation for managing chemotherapy-induced peripheral neuropathy, Role: Investigator, LLU Dept. of Medicine, (04/2025 - 04/2026) Status: Approved
  • Investigator Initiated: A phase II trial of preoperative chemotherapy (with gemcitabine and nab-paclitaxel) and stereotactic body radiotherapy followed by surgery and chemotherapy in patients with resectable pancreatic adenocarcinoma, Role: Investigator, LLU Dept. of Surgery, (09/2024 - 09/2025) Status: Approved
  • Retrospective analysis of acute Lymphoblastic Leukemia patients, Role: Investigator, LLU Dept. of Medicine, (02/2020 - 02/2021) Status: Completed
  • LLU Cancer Center biospecimen laboratory - specimens collection protocol, Role: Investigator, LLU Cancer Institute, (09/2024 - 09/2025) Status: Approved
  • Retrospective Analysis of EASIX Score for Prognostication of Newly Diagnosed Hematologic Malignancies at Loma Linda Medical Center from 1/1/2010 – 12/31/2024, Role: Investigator, LLU Cancer Institute, (03/2025) Status: Approved